Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance

Overview

• Repligen Q2 revenue rises 15% to $182 mln, beating analyst expectations

• Adjusted EPS for Q2 misses estimates at $0.37, per LSEG data

• Company raises full-year revenue guidance, citing strong non-COVID growth

Outlook

• Repligen raises 2025 revenue guidance to $715 mln-$735 mln

• Company expects 2025 organic non-COVID growth of 12.5%-15.5%

• Repligen sees 1% tailwind from foreign currency for 2025

• Company anticipates modest impact from tariff surcharges

Result Drivers

• STRONG DEMAND - Repligen reports over 20% year-over-year order growth, marking the eighth consecutive quarter of order growth exceeding non-COVID revenue

• PRODUCT PERFORMANCE - Consumables and capital equipment showed strong growth, with consumables up over 20% and capital equipment growing in the high-teens

• NEW PRODUCT LAUNCH - Introduction of ProConnex MixOne, a single-use mixer, contributing to portfolio strength

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Repligen Corp is $180.62, about 33.8% above its July 28 closing price of $119.65

• The stock recently traded at 63 times the next 12-month earnings vs. a P/E of 70 three months ago

Press Release: ID:nGNX7LWj4t